CFM
ADMA icon

Catalyst Funds Management’s ADMA Biologics ADMA Stock Holding History

Catalyst Funds Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,100
Closed -$184K – 482
2025
Q2 		$184K Buy
+10,100
New +$206K 0.05% 320
2024
Q4 		– Sell
-4,200
Closed -$84K – 317
2024
Q3 		$84K Buy
+4,200
New +$65.3K 0.02% 554

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Catalyst Funds Management's ADMA Position: Q3 2025 in Review

Catalyst Funds Management sold out of ADMA Biologics (ADMA) in Q3 2025, closing a stake of 10,100 shares — an estimated $184K sold.

Catalyst Funds Management first reported a position in ADMA in Q3 2024 and held it in 2 quarters. The position peaked at $184K in Q2 2025. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

  • Catalyst Funds Management reported no remaining ADMA Biologics position as of Q3 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 10,100 ADMA Biologics shares in Q3 2025, an estimated $184K.
  • Catalyst Funds Management first reported a position in ADMA Biologics in Q3 2024 and held it in 2 quarters.
  • Catalyst Funds Management's ADMA Biologics position peaked at $184K in Q2 2025.
  • 365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on Catalyst Funds Management's 13F filing for Q3 2025, filed 12 Nov 2025.